

Shasun Pharmaceuticals Limited

3rd & 4th Floor, 'Batra Centre', 28,Sardar Patel Road,Guindy, Chennai - 600032,Tamil Nadu, India

Press release

Successful completion of US FDA inspection

Chennai, 13th Novemebr 2014

Shasun Pharmaceuticals Ltd ("Shasun"),a global pharmaceutical organization offering world class capabilities and facilities has successfully completed US FDA inspection at its manufacturing facility at Dudley England. The USFDA audit was held on first week of November 2014.

On completion of the inspection the USFDA inspector concluded that the facility, systems and practices comply with USFDA requirements with <u>no observations reported on the form 483.</u>

About Shasun Pharmaceuticals Limited:

Shasun Pharmaceuticals Ltd, listed on the Bombay Stock Exchange Limited (stock code: 524552) and the National Stock Exchange of India Limited (stock code: SHASUNPHAR) is a leading manufacturer of APIs and formulations, catering to global customers, with world class capabilities and facilities. Shasun offers formulation and generic manufacturing services at its Indian sites together with a contract research and manufacturing services for APIs in India and UK. For more information about Shasun Pharmaceuticals Ltd please visit www.shasun.com.

For further information please contact:

Shasun Pharmaceutical Limited

Mr. S. Hariharan, Chief Financial Officer <u>hari@shasun.com</u> +91 98410 46299

Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Shasun Pharmaceuticals Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.